ACADIA Pharmaceuticals Inc.
$17.11-$0.48 (-2.7%)
Last close · Data as of Nov 20, 2026
- Market cap
- $3.7B
- P/E
- 9.5x
- EV / EBITDA
- 30.8x
- Revenue
- $1.1B
- Net margin
- 36.5%
- ROCE
- 8.1%
Price chart
Technical chartScreen technicals →-25.3% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -16.3%
- 3M
- -41.1%
- 6M
- -18.3%
- 1Y
- -25.3%
- 5Y
- -10.7%
52-week range
Day change -$0.48 (-2.7%) from $18 to $17 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in ACAD, bought on each weekday since 2021.
News & filings
What ACADIA Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthNet margin of 36.5% against a peer median of 8.1%.
Concerns (1)
- The price is 26.1% below its 200-day average, and the 50-day average is below the 200-day.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
Read moreShow less
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Shares outstanding
- 168.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $3.7B
- P/E
- 9.5x
- P/B
- 3.0x
- EV / EBITDA
- 30.8x
- EV / Sales
- 3.4x
- P/S
- 3.5x
- 52-week high
- $30.57
- 52-week low
- $16.50
Profitability
- Operating margin
- 9.8%
- Net margin
- 36.5%
- EBITDA margin
- 10.9%
- ROE
- 31.9%
- ROCE
- 8.1%
- ROA
- 25.0%
- Asset turnover
- 0.69
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $1.1B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 11.9%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 27.5%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 72.7%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $105.1M
Solvency
- Current ratio
- 3.83
- Debt / Equity
- 0.04
- Debt / Assets
- 0.03
- CFO / Net profit
- 0.28
- Cash / Market cap
- 4.8%
Where the revenue went
Of every $100 of FY2025 revenue, $36 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $89.0M |
| Revenue | Gross profit | $982.5M |
| Gross profit | Research and development | $328.8M |
| Gross profit | Selling, general and administrative | $548.9M |
| Gross profit | Other operating expenses | $10.0k |
| Gross profit | Operating income | $104.8M |
| Operating income | Pretax income | $104.8M |
| Interest and other income | Pretax income | $34.1M |
| Pretax income | Net income | $138.9M |
| Tax benefit and other | Net income | $252.1M |
Revenue and net profit
Revenue grew 11.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $517.2M | -$216.0M |
| FY2023 | $726.4M | -$61.3M |
| FY2024 | $957.8M | $226.5M |
| FY2025 | $1.1B | $391.0M |
Cash flows
FY2025: $109.8M from operations, $105.1M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$114.0M | -$114.0M |
| FY2023 | $16.7M | $16.7M |
| FY2024 | $157.7M | $157.2M |
| FY2025 | $109.8M | $105.1M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $1.1B+11.9%1Y
- EBITDA
- $116.6M+16.4%1Y
- Net profit
- $391.0M+72.7%1Y
- Cash from operations
- $109.8M-30.4%1Y
- Free cash flow
- $105.1M-33.1%1Y
- Revenue CAGR, 3Y
- 27.5%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $1.1B | $116.6M | $391.0M | $105.1M | 31.9% | +11.9% | +72.7% |
Monthly returns
Month-by-month returns of ACAD across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.6B |
| Current assets | $1.1B |
| Non-current assets | $502.1M |
| Liabilities | $336.8M |
| Current liabilities | $277.1M |
| Non-current liabilities | $59.7M |
| Equity | $1.2B |
| Paid-in capital | $3.0B |
| Retained earnings | -$1.8B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; ACAD highlighted.
P/E against peers
ACAD trades at 9.5x earnings against a peer median of 24.2x (a 61% discount).
Not shown (no positive earnings and no EV / Sales): RadNet, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc.ACADthis companyP/E ↓ discount | $3.7B | 9.5x | 3.0x | 31.9% | 30.8x |
| RadNet, Inc.RDNT | $4.2B | -222.6x | 3.8x | -1.7% | 16.7x |
| Veracyte, Inc.VCYT | $4.0B | 60.1x | 3.0x | 5.1% | 40.9x |
| Waystar Holding Corp.WAY | $3.9B | 34.6x | 1.0x | 2.9% | 13.6x |
| Catalyst Pharmaceuticals, Inc.CPRX | $3.8B | 17.9x | 4.0x | 22.5% | 10.6x |
| Merit Medical Systems, Inc.MMSI | $3.8B | 29.3x | 2.4x | 8.1% | 12.5x |
| Organon & Co.OGN | $3.5B | 18.8x | 4.7x | 24.9% | 9.0x |
| ICU Medical, Inc.ICUI | $3.4B | 4607.1x | 1.6x | 0.0% | 14.7x |
| Concentra Group Holdings Parent, Inc.CON | $3.2B | 19.2x | 8.1x | 42.3% | 12.7x |
| Peer median | — | 24.2x | 3.4x | 6.6% | 13.1x |
Year-to-date ROI
ACAD since 1 January, against earlier years.
Historical volatility
ACAD's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -43.2% |
| FY2023 | -10.1% |
| FY2024 | 8.8% |
| FY2025 | 9.8% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $1.1B |
| Cost of revenueCost Of Revenue | $89.0M |
| Gross profitGross Profit | $982.5M |
| Operating expensesOperating Expense | $877.7M |
| Research and developmentResearch And Development | $328.8M |
| Selling, general and administrativeSelling General And Administration | $548.9M |
| Total expensesTotal Expenses | $966.7M |
| Operating incomeOperating Income | $104.8M |
| Interest and other | |
| Pretax incomePretax Income | $138.9M |
| TaxTax Provision | -$252.1M |
| Net incomeNet Income | $391.0M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.6B |
| Current assetsCurrent Assets | $1.1B |
| Non-current assetsTotal Non Current Assets | $502.1M |
| LiabilitiesTotal Liabilities Net Minority Interest | $336.8M |
| Current liabilitiesCurrent Liabilities | $277.1M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $59.7M |
| EquityTotal Equity Gross Minority Interest | $1.2B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $109.8M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $109.8M |
| Net income, continuing operationsNet Income From Continuing Operations | $391.0M |
| Depreciation and amortisationDepreciation And Amortization | $11.8M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $11.8M |
| Depreciation | $870.0k |
| Amortization cash flowAmortization Cash Flow | $10.9M |
| Amortization of intangiblesAmortization Of Intangibles | $10.9M |
| Amortization of securitiesAmortization Of Securities | -$5.4M |
| Stock-based compensationStock Based Compensation | $52.1M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on investment securitiesGain Loss On Investment Securities | — |
| Change in working capitalChange In Working Capital | -$89.8M |
| Other non-cash itemsOther Non Cash Items | -$249.9M |
| Investing cash flowInvesting Cash Flow | -$302.6M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$302.6M |
| Capital expenditureCapital Expenditure | -$4.7M |
| Purchase of PP&EPurchase Of PPE | -$4.7M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$4.7M |
| AcquisitionsPurchase Of Business | -$98.8M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$98.8M |
| Purchase of investmentsPurchase Of Investment | -$692.6M |
| Sale of investmentsSale Of Investment | $493.5M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$199.0M |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | — |
| Financing cash flowFinancing Cash Flow | $49.9M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $49.9M |
| Shares issuedIssuance Of Capital Stock | $49.9M |
| Common stock issuedCommon Stock Issuance | $49.9M |
| Net common stock issuedNet Common Stock Issuance | $49.9M |
| Change in cashChanges In Cash | -$142.8M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 3.0% |
| Cash at the start of the yearBeginning Cash Position | $328.4M |
| Cash at the end of the yearEnd Cash Position | $185.5M |
| Free cash flowFree Cash Flow | $105.2M |
| Supplemental |
Learn while you research
Academy chapters picked for ACADIA Pharmaceuticals Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Value InvestingA P/E of 9.5 could be a value opportunity, or a value trap. Know the difference.7 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read